Enanta Pharmaceuticals Inc (ENTA)

[NY1972]

As RAV screening may be hit or miss and not mandated by FDA, will 12 week Zepatier see 10%-15% failure rate in GT1a patients? GILD should run a Harvoni v. Zepatier trial to show off nuc power.

BMY’s approved 2-DAA HCV regimen in Japan is showing a 20% failure rate, according to John Milligan on GILD’s MS webcast today.